|
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations in exons 9 and 20 were investigated in 76 primary human DLBCLs, 3 DLBCL cell lines (LY1, LY8, and LY10), and 9 related samples using polymerase chain reaction-based sequence analysis to assess the possible relevance of PIK3CA mutations in DLBCL to the PI3K/AKT pathway activation.
|
18382359 |
2008 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, CUDC-907, a small-molecule dual-acting inhibitor of both class I and II HDACs and class I PI3Ks, effectively suppresses the growth and survival of MYC-altered or MYC-dependent cancer cells, such as DH DLBCL and BRD-NUT fusion-positive NUT midline carcinoma (NMC) cells, and MYC protein downregulation is an early event induced by CUDC-907 treatment.
|
27980108 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, expression of the important components of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway and their clinical significance were investigated in 73 DLBCL cases.
|
23636313 |
2013 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that ROR1 is a novel prognostic marker for DLBCL survival and ROR1 significantly promotes DLBCL tumorigenesis by regulating the PI3K/Akt/mTOR signaling pathway.
|
30801854 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
|
31471373 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, in preclinical studies, the synergistic effects of PI3K inhibitors and HDAC inhibitors on DLBCL have sparked the enthusiasm of researchers to target both PI3K and HDAC.
|
28756223 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Established DLBCL cell lines were treated with either rituximab or obinutuzumab alone or in combination with PI3K delta inhibitor idelalisib.
|
29617050 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-κB in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.
|
21173233 |
2011 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma.
|
26961147 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
|
25909227 |
2015 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results of Bioinformatics analysis revealed that the target genes including NEDD4L and UBA52 and several associated pathways including PI3K/AKT and MAPK/ERK might be involved in the development of CD5+ R/R DLBCL.
|
31775867 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We analyzed cancer-specific biclusters and found that the PI3K/Akt signaling pathway is strongly enriched with targets of a few miRNAs in breast cancer and diffuse large B-cell lymphoma.
|
30820547 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Constitutive activation of IGF-1R, MEK, or PI3K pathways was sufficient to confer resistance to EZH2 inhibitors in DLBCL.
|
29572378 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings highlight the important role of cAMP signaling in DLBCL and suggest that clinically relevant PDE4 and PI3K/AKT inhibitors might be useful in the treatment of DLBCL and additional B-lymphoid malignancies with increased PDE4B expression.
|
15331441 |
2005 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-κB in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.
|
21173233 |
2011 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, our work identifies an additional mechanism of synergy between PI3K pathway inhibitors and BCL-2 antagonists that strengthens the rationale for testing this combination in DLBCL.
|
26460954 |
2015 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.
|
25215588 |
2014 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, the aim of the study is to investigate the CNV of PI3K subunits and their relationship with clinicopathological features exploring the possible mechanism underlying of PI3K activation in DLBCL.
|
24418330 |
2014 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In a high-throughput combinatorial drug screening experiment, BETi enhance the antiproliferative effects of PI3K inhibitors in a panel of diffuse large B cell lymphoma (DLBCL) and Burkitt lymphoma cell lines.
|
30134175 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
|
28178345 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we examined the mechanism by which the cyclic-AMP/PDE4 signaling axis suppresses PI3K, toward identifying a novel mechanism-based combinatorial strategy to attack BCR-dependency in mature B-cell malignancies.<b>Experimental Design:</b> We used <i>in vitro</i> and <i>in vivo</i> diffuse large B-cell lymphoma (DLBCL) cell lines and primary chronic lymphocytic leukemia (CLL) samples to preclinically evaluate the effects of the combination of the FDA-approved phosphodiesterase 4 (PDE4) inhibitor roflumilast and idelalisib on cell survival and tumor growth.
|
29246942 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our study showed that PIK3CD can promote proliferation of DLBCL cells both in vitro and in vivo, suggesting that PIK3CD could be druggable in the therapy of DLBCL.
|
27448819 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.
|
23764004 |
2013 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In DLBCL lines, TMD8 was the most sensitive to ibrutinib (GI<sub>50</sub> = 0.001); combinations with BCL-2 inhibitor ABT-199, and PI3K inhibitors IPI-145 and GDC-0941 showed the strongest synergistic activity.
|
28750570 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
|
28202458 |
2017 |